LCT In The News

1 October 2022

Australasian Technology - "Advancing groundbreaking Parkinson's disease research"

Australasian biotech company Living Cell Technologies (ASX:LCT) is advancing potentially groundbreaking research into Parkinson’s disease, with the goal of developing a unique treatment to prevent progression of the disease, reports Australasian Biotechnology.

23 August 2022

Biotech Dispatch - "Choroid plexus tissue shipped to Sydney as NTCELL research advances"

Living Cell Technologies (ASX:LCT) has advanced its Parkinson's disease research with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL, reports Biotech Dispatch.

1 June 2022

Australian Pork - "Artificial intelligence and pig brain tissue combat Parkinson's"

31 May 2022

Market Herald - "Living Cell Technologies (ASX:LCT) raises $1.28m for NTCELL"

Biotech company Living Cell Technologies (LCT) has raised $1.285 million through a private placement to boost its research into Parkinson’s Disease, reports The Market Herald.

23 May 2022

Kalkine Media - "Major Breakthrough! Living Cell Technologies (ASX:LCT) to use AI in research for Parkinson’s"

LCT is set to apply AI in NTCELL research to augment the quality of its third clinical trial in Parkinson’s disease, reports Kalkine Media.

31 March 2022

Biotech Dispatch - "NTCELL to be produced in Australia under UTS research agreement"

NTCELL will be produced in Australia under a research agreement with the University of Technology Sydney and the Australian Foundation for Diabetes Research, reports Biotech Dispatch.